Selvacovatein

Selvacovatein is a recombinant protein vaccine candidate under development for prevention of respiratory syncytial virus (RSV) infection, engineered to present the RSV prefusion F protein in a stabilized conformation to elicit potent neutralizing antibody responses. The prefusion conformation exposes epitopes that are the primary targets of broadly neutralizing antibodies, making it a preferred antigen for next-generation RSV vaccines. It represents a structure-based vaccine design approach targeting the most immunologically relevant conformational state.

As a monoclonal antibody, it binds with high specificity to its target antigen, modulating the immune response through mechanisms including receptor blockade, immune cell engagement, or targeted cytotoxicity.

Yes, Selvacovatein is an approved drug. It has reached clinical phase 4. It is classified as a Protein.